Search Results for keywords:"hearing request"

The Drug Enforcement Administration (DEA) has announced that Sterling Pharma USA LLC has submitted an application to become a bulk manufacturer of controlled substances. Specifically, they plan to produce Tetrahydrocannabinols from hemp extract. People who are currently registered as bulk manufacturers of these substances, or who are applying to be, have the opportunity to file comments or objections regarding this application by April 6, 2021. They can also request a hearing before the same deadline.

The Drug Enforcement Administration (DEA) has announced that the Research Triangle Institute has applied to become a bulk manufacturer of certain controlled substances. The institute intends to produce these substances synthetically for research purposes and to provide analytical reference standards. Interested parties can submit electronic comments or objections regarding this registration by June 17, 2025, and can request a hearing by the same date. Comments are to be submitted through the Federal eRulemaking Portal at regulations.gov.

The Securities and Exchange Commission has issued a notice regarding Marqeta, Inc.'s application for an order under the Investment Company Act of 1940. Marqeta seeks to be recognized as primarily engaging in business activities other than investing in securities, focusing on providing a payment card issuing platform. The application details Marqeta's operations, historical development, and financial practices to demonstrate that it does not function as an investment company. The SEC invites interested parties to request a hearing concerning the application with a deadline in March 2025.

Sigma Aldrich Research Biochemicals Inc. has applied to the Drug Enforcement Administration to become a registered bulk manufacturer of certain controlled substances. The company intends to produce these substances for use as reference standards only, and no other uses are approved under this registration. The public can submit comments or objections electronically regarding this application until May 12, 2025, through the Federal eRulemaking Portal. Additionally, requests for a hearing on the application must also be made by this date.

The Securities and Exchange Commission (SEC) has published a notice regarding an application for an order under the Investment Company Act of 1940. The order would grant exemptions from certain sections of the Act and a rule under it, allowing ActiveShares ETFs to issue and redeem shares in large batches, and facilitate market transactions at negotiated prices. The application involves the ActiveShares ETF Trust, Legg Mason Partners Fund Advisor, LLC, and Legg Mason Investor Services, LLC, seeking relief consistent with a prior order. The SEC will issue the order unless someone requests a hearing by February 8, 2021, by contacting the SEC via email.

Leading Pharma LLC has applied to register as an importer of controlled substances. This application is for research and development purposes, aiming toward creating a new pharmaceutical product that is pending approval by the Food and Drug Administration (FDA). Interested parties can submit comments or request a hearing regarding this application, with a deadline of January 17, 2025. The Drug Enforcement Administration (DEA) will approve the application only if it meets specific legal criteria.

Patheon Pharmaceuticals Inc. has applied to the Drug Enforcement Administration to become a registered bulk manufacturer of certain controlled substances. The company plans to use these substances as Active Pharmaceutical Ingredients in FDA-approved medications. Anybody interested can submit comments or objections electronically by May 12, 2025, through the Federal eRulemaking Portal. Requests for a hearing regarding this application are also due by the same date.

Cedarburg Pharmaceuticals has applied to the Drug Enforcement Administration (DEA) to become a registered bulk manufacturer of controlled substances. The company plans to produce synthetic Tetrahydrocannabinols (THC) as an active pharmaceutical ingredient for distribution. Interested parties, including current manufacturers or applicants, can submit comments or request a hearing regarding this application by March 15, 2021. The DEA is handling correspondence related to this application.

S&B Pharma, Inc. has applied to the Drug Enforcement Administration (DEA) to be registered as an importer of certain controlled substances. The company intends to import intermediate forms of Tapentadol for manufacturing purposes and ANPP to produce other controlled substances, but they will not import finished products for commercial sale. Interested parties, such as registered manufacturers, can submit comments, objections, or request a hearing regarding this application by March 18, 2021.

The Securities and Exchange Commission (SEC) published a notice about an application by Goldman Sachs Private Credit Corp. and Goldman Sachs Asset Management, L.P. The applicants are seeking an exemption from certain sections of the Investment Company Act of 1940 to allow certain registered closed-end investment companies to issue different classes of shares with varying fees. The SEC indicates that unless a hearing is requested by April 14, 2025, an order granting the requested relief will be issued. Interested parties can find more details by accessing the applicant's amended application on the SEC's EDGAR system.